What Is N-Acetyl Semax Amidate? Complete Research Guide (2026)
The ACTH-derived peptide family has a research history that begins with an observation most neuroscientists know from endocrinology textbooks: fragments of adrenocorticotropic hormone, the pituitary stress hormone, produce cognitive effects in rodent models that have nothing to do with cortisol. ACTH’s primary function is stimulating cortisol release from the adrenal cortex. But when researchers isolated its central sequence — specifically the amino acids at positions 4 through 10 — they found a fragment that retained the cognitive and neurological activity of the parent hormone without producing any of the hormonal effects. No cortisol release. No adrenal stimulation. Just the CNS component in isolation.
Semax was built on that finding. And N-Acetyl Semax Amidate is the structurally modified version that took Semax’s CNS activity and extended it with pharmacokinetic improvements that make it a more stable and practically useful research tool. Understanding why it exists, what the modifications do, and how its research profile relates to but extends beyond the original Semax literature is what this guide covers.
What N-Acetyl Semax Amidate Is
N-Acetyl Semax Amidate is a synthetic heptapeptide with the sequence Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2. The core sequence — Met-Glu-His-Phe-Pro-Gly-Pro — is identical to Semax, itself a synthetic analog of the ACTH(4-10) fragment extended with a Pro-Gly-Pro tripeptide at the C-terminus that improves metabolic stability compared to the shorter parent sequence. The two modifications that distinguish N-Acetyl Semax Amidate from Semax add protection at both termini simultaneously: N-terminal acetylation blocks aminopeptidase attack from the front end of the molecule, and C-terminal amidation blocks carboxypeptidase attack from the back end.
The result is a compound with substantially extended metabolic stability in biological environments compared to both unmodified Semax and the singly-modified N-Acetyl Semax variant. Where Semax is degraded in biological environments within minutes by terminal exopeptidases, N-Acetyl Semax Amidate’s dual-protected termini substantially delay that degradation — extending the window during which the compound remains intact and biologically active. The modifications target pharmacokinetics rather than pharmacodynamics: the compound’s receptor interactions and CNS mechanisms are preserved from the Semax backbone, but the compound persists longer before enzymatic cleavage terminates its activity.
Compound specifications:
| Property | Detail |
|---|---|
| Full name | N-Acetyl Semax Amidate |
| Abbreviation | NASA |
| Sequence | Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2 |
| Amino acids | 7 (heptapeptide) |
| Parent compound | Semax — ACTH(4-10) + Pro-Gly-Pro extension |
| CAS number | 2920938-90-3 |
| Molecular formula | C39H54N10O10S |
| Molecular weight | ~854.97 to 858.98 g/mol |
| N-terminal modification | Acetylation — aminopeptidase protection |
| C-terminal modification | Amidation — carboxypeptidase protection |
| Primary mechanisms | BDNF upregulation, MC4R activation, TrkB sensitization, monoamine modulation |
| Blood-brain barrier | Crosses via olfactory/trigeminal pathways |
| Clinical approval | Semax approved in Russia for stroke and cognitive impairment |
| FDA status | Not approved — research use only |
| Supplied form | Lyophilized powder |
| Vial size | 30mg |
| Storage lyophilized | -20°C up to 24 months |
| Storage reconstituted | 2-8°C up to 28 days |
The Semax Family — Four Variants, Four Stability Profiles
Researchers working with ACTH-derived peptides encounter four related compounds, each with a distinct stability profile and slightly different research utility. Understanding the distinctions matters for selecting the right tool for a given protocol.
Semax is the original compound — ACTH(4-10) extended with Pro-Gly-Pro. It has the strongest direct human clinical evidence base of the four variants. It is approved for intranasal use in Russia for stroke recovery and cognitive impairment treatment, giving it a clinical anchor that none of the modified variants yet have. Its limitation as a research tool is relatively rapid enzymatic degradation in biological environments.
N-Acetyl Semax adds only N-terminal acetylation — blocking aminopeptidase attack from the front end. This improves stability compared to unmodified Semax but leaves the C-terminal carboxypeptidase vulnerability intact.
Semax Amidate adds only C-terminal amidation — blocking carboxypeptidase attack from the back end. The N-terminus remains unprotected.
N-Acetyl Semax Amidate (NASA) incorporates both modifications simultaneously. Both degradation entry points are blocked, producing the most metabolically stable variant of the family. This makes it the most practical choice for research protocols requiring extended compound stability — though it carries the least direct human clinical data, since all the landmark Semax clinical work was done with the unmodified original.
| Variant | N-Terminal | C-Terminal | Stability | Clinical Data |
|---|---|---|---|---|
| Semax | Free | Free | Lowest | Most extensive |
| N-Acetyl Semax | Acetylated | Free | Moderate | Limited |
| Semax Amidate | Free | Amidated | Moderate | Limited |
| N-Acetyl Semax Amidate | Acetylated | Amidated | Highest | Least direct |
The ACTH Connection — Where This Compound Comes From
Understanding N-Acetyl Semax Amidate’s mechanisms requires understanding the ACTH(4-10) sequence that forms its core. ACTH — adrenocorticotropic hormone — is a 39-amino acid peptide produced by the pituitary gland that drives cortisol production from the adrenal cortex. That is its well-known endocrine function. What is less commonly discussed in endocrinology contexts is that ACTH also has direct CNS activity — effects on cognition, memory, attention, and neuroprotection that are mediated by different receptors entirely from those involved in adrenal stimulation.
Specifically, the ACTH(4-10) fragment — amino acids 4 through 10 of the parent hormone — retains the CNS-relevant activity without producing hormonal effects. No cortisol release. No adrenal stimulation. No HPA axis involvement. This dissociation between hormonal and CNS activity was the scientific foundation on which Semax was built: extend the ACTH(4-10) sequence, add pharmacokinetic improvements, and produce a research tool that isolates the cognitive and neuroprotective CNS activity of ACTH from its endocrine functions.
N-Acetyl Semax Amidate sits two structural steps further down that development path — built on Semax, which was built on ACTH(4-10). Its mechanisms are extensions of the same ACTH-fragment pharmacology, enhanced by the stability modifications that make them accessible in research protocols requiring sustained compound presence.
How N-Acetyl Semax Amidate Works — The Mechanisms
N-Acetyl Semax Amidate operates through several intersecting neurochemical systems simultaneously. Its profile is excitatory and cognitive in orientation — which directly complements the inhibitory and emotional profile of N-Acetyl Selank Amidate in combined research protocols, since the two compounds address different CNS axes through non-overlapping mechanisms.
BDNF Upregulation
The most consistently documented and scientifically significant mechanism in the Semax research literature is BDNF (brain-derived neurotrophic factor) upregulation. Published research has shown that Semax enhances BDNF levels by approximately 1.4 times and doubles the expression of TrkB receptors — the primary high-affinity receptor through which BDNF exerts its biological effects.
BDNF is the most widely distributed neurotrophin in the mammalian brain. It drives neuronal survival, promotes dendritic growth and synaptic strength, mediates long-term potentiation — the molecular basis of memory consolidation — and is one of the primary molecular mediators of neuroplasticity. Declining BDNF is associated with depression, neurodegenerative conditions, and cognitive impairment in the research literature. A compound that reliably elevates BDNF and simultaneously upregulates TrkB receptor expression — making neural tissue more responsive to both endogenous and compound-stimulated BDNF — is a meaningful research tool for studying neuroplasticity, cognitive function, and neuroprotective mechanisms.
The TrkB upregulation is particularly relevant: even if BDNF concentrations increase, the magnitude of the downstream cellular response depends on receptor density. By increasing both the ligand (BDNF) and the receptor (TrkB) simultaneously, N-Acetyl Semax Amidate produces a compound neuroplasticity signal that has both quantitative and sensitivity dimensions.
MC4R Activation and Monoamine Modulation
Melanocortin 4 receptor (MC4R) activation is central to N-Acetyl Semax Amidate’s cognitive and attention-related research profile. MC4R is the primary brain melanocortin receptor and is expressed extensively in the hippocampus, prefrontal cortex, and hypothalamus — regions involved in learning, memory, attention regulation, and executive function. The ACTH-fragment lineage of Semax means it carries native melanocortin receptor binding activity, placing it in a mechanistically distinct category from compounds that act on cognitive function through monoamine reuptake inhibition or other approaches.
Alongside MC4R activation, Semax research has documented modulation of serotonin and dopamine neurotransmitter systems. Interactions with enkephalin (opioid) signaling have also been characterized in the published literature. These monoamine effects contribute to attention and focus-related research applications — not through direct agonism at serotonin or dopamine receptors, but through modulation of the endogenous systems that regulate neurotransmitter availability and receptor sensitivity in the prefrontal cortex and limbic structures.
NGF Upregulation
Nerve growth factor (NGF) — a second neurotrophin — is also upregulated in Semax research models alongside BDNF. NGF’s primary role involves the survival and maintenance of cholinergic neurons in the basal forebrain, which are critical for memory consolidation and attention and are among the first neuronal populations to be lost in Alzheimer’s disease progression. Research examining whether BDNF and NGF upregulation together produce different outcomes than BDNF upregulation alone uses N-Acetyl Semax Amidate as a tool for studying dual neurotrophin elevation in controlled laboratory conditions.
Broad Gene Expression Effects
A 2017 genome-wide study by Dergunova et al. and subsequent proteomic analyses by Filippenkov et al. (2021) revealed that Semax affects the expression of hundreds of genes across multiple functional categories — an observation that has expanded the mechanistic picture of this compound class significantly beyond the BDNF and monoamine frameworks that initially characterized it. These transcriptomic findings suggest biological activity substantially broader than any single receptor mechanism can account for, making the compound relevant for research examining systems-level neurobiological responses rather than just individual molecular targets.
What the Clinical Evidence Shows — Semax Research Foundation
Because direct published research on N-Acetyl Semax Amidate as a specific compound is more limited than the broader Semax literature, the clinical evidence base comes primarily from Semax studies — the parent compound whose mechanisms N-Acetyl Semax Amidate preserves while extending stability.
Stroke recovery: Semax is approved in Russia for stroke treatment. A published clinical trial in 110 stroke patients examined intranasal Semax administration and documented elevated plasma BDNF levels alongside improved motor skills and functional independence outcomes. The BDNF elevation mechanism is the same one that N-Acetyl Semax Amidate activates through the same core sequence.
Cognitive function: Published research has shown Semax effects on learning and memory consolidation in rodent models across multiple testing paradigms. The Dolotov et al. 2006 study published in Brain Research characterized Semax’s regulation of BDNF and TrkB expression in the rat hippocampus — one of the foundational mechanistic papers in the Semax literature.
Immune modulation: Semax research has documented neuroimmune effects — interactions with immune function mediated through its ACTH-fragment activity. This neuroimmune dimension gives the compound research relevance at the intersection of CNS and immune system function, separate from its cognitive and neuroprotective applications.
N-Acetyl Semax Amidate vs. N-Acetyl Selank Amidate — Complementary CNS Research Tools
These two compounds are frequently studied together in combined research protocols because they address different CNS axes through non-overlapping mechanisms. Understanding how they differ is fundamental to research design.
| Feature | N-Acetyl Semax Amidate | N-Acetyl Selank Amidate |
|---|---|---|
| Parent compound | Semax — ACTH(4-10) analog | Selank — tuftsin analog |
| Primary CNS axis | Excitatory/cognitive | Inhibitory/emotional |
| BDNF upregulation | Yes — cortical and hippocampal | Yes — hippocampal |
| Dopaminergic activity | Yes — monoamine modulation | No primary activity |
| GABAergic activity | No | Yes — positive allosteric modulation |
| Serotonin interaction | Yes | Yes |
| MC4R activation | Yes | No |
| NGF upregulation | Yes | Limited |
| Immunomodulatory | Yes — ACTH fragment lineage | Yes — tuftsin lineage |
| Clinical approval (parent) | Semax — stroke, Russia | Selank — anxiety, Russia |
| Primary research angle | Cognition, neuroprotection, attention | Anxiety, stress response, neuro-immune |
Semax activates the excitatory and cognitive CNS axis. Selank activates the inhibitory and emotional axis. In combined protocols, they provide complementary tools for studying both dimensions of CNS function simultaneously without mechanistic redundancy — each compound addressing what the other does not.
Research Applications
N-Acetyl Semax Amidate is examined in laboratory settings across several intersecting CNS research domains. BDNF and TrkB pathway research uses it to study how ACTH-derived peptides upregulate neurotrophin expression and receptor sensitivity in hippocampal and cortical models, examining how simultaneous increases in both BDNF ligand and TrkB receptor density amplify neuroplasticity signals compared to single-target interventions.
MC4R pharmacology research examines how melanocortin receptor 4 activation in prefrontal and hippocampal tissue influences attention regulation, working memory, and executive function in rodent behavioral models. Neuroprotection research uses N-Acetyl Semax Amidate in ischemic, excitotoxic, and oxidative stress models to study how BDNF and NGF upregulation protects neuronal populations from damage — with particular relevance in models examining neurodegenerative disease pathways. Cognitive modulation research examines learning, memory consolidation, and attention in standard rodent behavioral testing paradigms, using the extended stability of the dual-modified form to maintain consistent compound presence across multi-session experimental protocols.
Comparative analog research uses it alongside Semax, N-Acetyl Semax, and Semax Amidate to isolate the specific contribution of each structural modification to biological activity, stability, and CNS penetration — providing a clean framework for structure-activity relationship research within the ACTH-derived peptide class. Combined CNS research uses N-Acetyl Semax Amidate alongside N-Acetyl Selank Amidate to study both the excitatory/cognitive and inhibitory/emotional CNS axes simultaneously, with each compound addressing mechanisms the other does not activate.
Quality Standards
Research on BDNF pathways, MC4R pharmacology, and neuroprotection is sensitive to compound integrity in ways that make independent testing documentation non-negotiable for producing interpretable results.
HPLC purity analysis confirming at least 99% compound purity is the baseline. In CNS research where receptor binding affinities and neurotrophin upregulation are quantitative endpoints, even small impurity concentrations introduce uncontrolled variables that compromise result interpretation. Mass spectrometry identity confirmation verifies that the compound’s molecular weight and fragmentation pattern match N-Acetyl Semax Amidate’s known profile — confirming the dual modifications are present and intact. Endotoxin screening is specifically relevant in neuroinflammation research, where endotoxin contamination produces inflammatory responses that directly confound outcomes in any protocol examining neuroprotection or neuroimmune function. Sterility testing confirms the absence of microbial contamination.
All Patriot Peptides N-Acetyl Semax Amidate (30mg) is manufactured in a cGMP-certified US facility and independently tested by a certified third-party laboratory across all four criteria. Batch-specific Certificates of Analysis are available for all products. For laboratory research use only.
Frequently Asked Questions
What is N-Acetyl Semax Amidate? N-Acetyl Semax Amidate is a dual-modified synthetic heptapeptide derived from Semax, itself an analog of the ACTH(4-10) fragment. It adds N-terminal acetylation and C-terminal amidation to the Semax backbone, blocking both primary enzymatic degradation pathways and extending metabolic stability in biological environments. It is studied in laboratory settings for BDNF and NGF upregulation, MC4R activation, monoamine system modulation, and neuroprotective mechanism research.
How does N-Acetyl Semax Amidate differ from regular Semax? Semax is the unmodified original compound with the strongest direct human clinical evidence base — including regulatory approval in Russia for stroke treatment. N-Acetyl Semax Amidate adds N-terminal acetylation and C-terminal amidation to extend metabolic stability. The modifications target pharmacokinetics rather than pharmacodynamics — the CNS mechanisms are preserved from the Semax backbone, but the compound lasts longer before enzymatic degradation terminates its activity.
What mechanisms does N-Acetyl Semax Amidate work through? The primary mechanisms documented in the Semax literature — which N-Acetyl Semax Amidate preserves through its identical core sequence — are BDNF upregulation by approximately 1.4 times, TrkB receptor expression doubling, NGF upregulation, MC4R activation in hippocampal and prefrontal cortex, and modulation of serotonin, dopamine, and enkephalin neurotransmitter systems. Genome-wide studies have documented effects across hundreds of genes in multiple functional categories.
What is the difference between N-Acetyl Semax Amidate and N-Acetyl Selank Amidate? Semax derivatives modulate the excitatory and cognitive CNS axis through BDNF, TrkB, MC4R, and dopamine. Selank derivatives modulate the inhibitory and emotional axis through GABA positive allosteric modulation and serotonin. They are mechanistically complementary — each addresses what the other does not — which is why combined protocols using both compounds are a growing area of CNS research.
Is N-Acetyl Semax Amidate FDA approved? No. It is not approved by the FDA for any indication. The parent compound Semax is approved for clinical use in Russia for stroke recovery and cognitive impairment. N-Acetyl Semax Amidate is available for legitimate laboratory research use only.
Where can I buy research-grade N-Acetyl Semax Amidate? Patriot Peptides N-Acetyl Semax Amidate (30mg) is manufactured in a cGMP-certified US facility and independently third-party tested for HPLC purity, mass spectrometry identity, endotoxin, and sterility. Batch-specific Certificates of Analysis are available. For laboratory research use only.
All content is for informational and educational purposes only. All Patriot Peptides products are strictly for laboratory research use only. Not for human consumption, veterinary use, or clinical application.
Related reading: N-Acetyl Selank Amidate (30mg) | What Is N-Acetyl Selank Amidate? | Semax (30mg) | How to Store Lyophilized Peptides